MTOR and neoplasm: Together with evidence that combination mTOR and MEK blockade enhanced on-treatment growth suppression of non-immunogenic MOC2 tumors, our findings of altered tumor immunity following MEK inhibition and preserved immunity following mTOR inhibition in immunogenic MOC1 tumors suggests the need for individual patient anti-cancer therapies to be tailored not only to identified oncogenic pathways but also to the immune status of the tumor.